Biomedicine & Pharmacotherapy · 2019 · 32 citations · 38 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis PharmacologyCell Cycle PharmacologyMitotic InhibitorsOncology PharmacologyAnti-apoptotic AgentsAnticancer ActivityAnticancer Natural ProductsCancer Cell Proliferation InhibitionCell Cycle Arrest MechanismsCell Cycle InhibitorsCell Viability AssaysCytotoxicity Assays
Kusunokinin is a potent lignan compound with a several biological properties including antitrypanosomal and anticancer. In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells. The result showed that (±)-kusunokinin and (±)-bursehernin represented the strongest growth inhibition against breast cancer (MCF-7) and cholangiocarcinoma (KKU-M213) cells with the IC50 values of 4.30 ± 0.65 μM and 3.70 ± 0.79 μM, respectively, both of which were lower than IC50 of normal fibroblast cells (L929). Etoposide was used as a positive control since this chemotherapeutic drug is in the lignan group same as (±)-kusunokinin. Surprisingly, etoposide showed less cytotoxicity than (±)-kusunokinin and its derivative on MCF-7, HT-29, KKU-M213 and KKU-K100. Moreover, (±)-bursehernin induced cell cycle arrest at G2/M phase, meanwhile (±)-kusunokinin tended to increased cell population at G2/M phase but did not show the significant difference compared with non-treated cells. Interestingly, protein levels related to cell proliferation pathway (topoisomerase II, STAT3, cyclin D1, and p21) were significantly decreased at 72 h. Both compounds induced apoptotic cell in time-dependent manner as confirmed by MultiCaspase assay. In conclusion, synthetic compound, (±)-kusunokinin and (±)-bursehernin, showed anticancer effects via the reduction of cell proliferation proteins and induction of apoptosis.
38
Epigenetic and genetic features of 24 colon cancer cell lines
D. Ahmed, Peter W. Eide, Ina A. Eilertsen et al. · Oncogenesis · 2013 · 906 citations · Full text
Anti-cancer potential of flavonoids: recent trends and future perspectives
Priya Batra, Anil Kumar Sharma · 3 Biotech · 2013 · 543 citations · Full text
Medicine, Oncology, Pharmacology +14